Cat. No.: HY-13567

Bendamustine

(Synonyms: SDX-105 free base)

6 Cited Publications

고객리뷰

Based on 6 publication(s) in Google Scholar

Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 98.0%
CAS No.: 16506-27-7
화학식: C₁₆H₂₁Cl₂N₃O₂
분자량:358.26

보관:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Bendamustine Chemical Structure

CAS No.: 16506-27-7

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
용액&용해도
- In Vitro
- In Vivo
Protocol
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

DNA Alkylator/Crosslinker^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>92.93 μM Compound: Bendamustine	Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay	10.1007/s00044-011-9959-8
HCT-116	IC₅₀	71.69 μM Compound: Bendamustine	Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 hr by MTT assay	10.1007/s00044-011-9959-8
HeLa	IC₅₀	>20 μM Compound: Bendamustine	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	[PMID: 33261898]
HeLa	IC₅₀	>20 μM Compound: Bendamustine	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 35477142]
HeLa	IC₅₀	>20 μM Compound: Bendamustine	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation	[PMID: 35944852]
HL-60	IC₅₀	6.98 μM Compound: Bendamustine	Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) HL60 cells after 24 hr by MTT assay	10.1007/s00044-011-9959-8
KB	IC₅₀	41.28 μM Compound: Bendamustine	Cytotoxicity against Homo sapiens (human) KB cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) KB cells after 24 hr by MTT assay	10.1007/s00044-011-9959-8
MDA-MB-231	IC₅₀	13.28 μM Compound: Bendamustine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 5 days by beckman coulter counting method	[PMID: 33261898]
MDA-MB-231	IC₅₀	13.28 μM Compound: Bendamustine	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 35477142]
MDA-MB-231	IC₅₀	13.28 μM Compound: Bendamustine	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation	[PMID: 35944852]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	70 μM Compound: 55	Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay	[PMID: 29870668]
Panel NCI-60 (60 carcinoma cell lines)	IC₅₀	2.2 μM Compound: 35; CY190602	Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition	[PMID: 33143937]
Panel NCI-60 (60 carcinoma cell lines)	IC₅₀	77 nM Compound: 161	Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines) Cytotoxicity against human Panel NCI-60 (60 carcinoma cell lines)	[PMID: 33077264]
Panel NCI-60 cells	GI₅₀	70 μM Compound: 55	Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI60 cells after 48 hrs by SRB assay	[PMID: 29870668]

In Vitro

Bendamustine is a DNA cross-linking agent that causes DNA breaks, with alkylating and antimetabolite properties. Bendamustine uniquely regulates apoptosis pathways and DNA repair pathways in non-Hodgkin's lymphoma cells. Bendamustine (50 μM) induces p21 (Cip1/Waf1) and NOXA genes, and increases the expression of p53 in SU-DHL-1 cells. Bendamustine (25 μM) blocks mitotic checkpoints and cuases mitotic catastrophe^[1].
Bendamustine reduces the viability of multiple myeloma (MM) cell lines, such as RPMI-8226 and 8226-LR5 cells, with IC₂₅s of 101.8 μM and 585.5 μM after 24 h incubation, and 51.7 and 374.3 μM after 48 h incubation, respectively. Bendamustine induces a specific caspase-dependent MM cell death and inhibits the spindle-assembly checkpoint^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bendamustine (25 mg/kg, i.v.) shows potent inhibition on the growth of tumor cells by 91%, 99% and 95% for DoHH-2, Granta 519 and RAMOS models, respectively. Moreover, the antitumor effect of Bendamustine is enhanced by rituximab in DoHH-2 and RAMOS models, but not in Granta 519 model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 16506-27-7
Appearance Solid
분자량 358.26
화학식 C₁₆H₂₁Cl₂N₃O₂
Color White to off-white
SMILES

O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
Synonyms

SDX-105 free base
선적

Room temperature in continental US; may vary elsewhere.
보관

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (6)

All IF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Leukemia

del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia. [Abstract]

2023 Nov;37(11):2221-2230. PMID: 37752286
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
J Biomed Res

2017 0(0): 1-12.

Bendamustine purchased from MedChemExpress. Usage Cited in: J Biomed Res. 2017 0(0): 1-12.

Testis cross-sections are stained with anti-PLZF antibody (red), and Hoechst 33342 (blue). Higher magnification images showing localization of PLZF-positive spermatogonia stem cells at the base of the seminiferous epithelium in contact with the basal membrane (arrows indicate PLZF+cells). A, B: sections from the testis of Bendamustine (BD) control mice and BD treated mice.
Patent

US20160222465A1.

용액&용해도

In Vitro:

DMSO : 100 mg/mL (279.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7913 mL

13.9563 mL

27.9127 mL

5 mM

0.5583 mL

2.7913 mL

5.5825 mL

10 mM

0.2791 mL

1.3956 mL

2.7913 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Cytotoxicity of both Bendamustine and melphalan on multiple myeloma (MM) cells is calculated as inhibition of cell viability by measuring the percentage of cell survival by MTS assay. Briefly, cells (1 × 10⁴/well) are seeded in 96-well plates with increasing concentrations of the drug and analyzed after 24, 48, 72 and 96 h of incubation. To this end, 1 μg/mL of MTS solution is added to each well and, after 1 h at 37 °C, the dark blue formazan crystals are dissolved by isopropanol 1 N and HCl (24:1, vol/vol). Finally, the absorbance is measured at 490 nm in a 96-well plate reader. Cell survival is estimated as the percentage of the absorbance of untreated controls and each test is performed in triplicate. The inhibitory concentrations 50 (IC₅₀) and 25 (IC₂₅) of each drug, being the amount able to reduce cell growth to 50% and 25%, respectively, of that of untreated control cells, are calculated, and the tests are performed in parallel using equitoxic concentrations of Bendamustine and melphalan. The relative resistance index (RRI) is expressed as the ratio of the IC₅₀ of 8226-LR5 to the IC₅₀ of RPMI-8226 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
C.B.-17 scid mice (DoHH-2, Granta 519) or C.B.-17 scid-bg mice (SuDHL-4, RAMOS) are inoculated with 1 × 10⁶ (DoHH-2, RAMOS), 3 × 10⁶ (SuDHL-4) or 5 × 10⁶ (Granta 519) cells s.c. in the right flank. For flank xenografts, inoculation volume is 0.2 mL consisting of a 50:50 mixture of cells in growth medium and Matrigel. Tumour volume is estimated by two to three weekly measurements of the length and width of the tumour by electronic calipers and applying the following equation: V=L×W²/2. Tumours are allowed to reach approximately 250 mm³, and mice are size-matched (day 0) into treatment and control groups. For systemic Granta 519 tumour models, 2 × 10⁶ cells are injected via the tail vein in 0.1 mL volume of cell medium on day 0, and treatment is initiated on day 14. All animals are ear-tagged and monitored individually throughout the experiment. Navitoclax is administered by oral gavage once daily in a mixture of Phosal 50PG : PEG400 : ethanol. Bendamustine and rituximab are administered i.v. at 25 mg/kg and 10 mg/kg, respectively, on day 1. Navitoclax is administered approximately 2 h before Bendamustine and rituximab. All trials are comprised of 10 mice per group. Mice are humanely killed when tumours reach a size >2000 mm³ or when any signs of distress are monitored. Signs of distress include loss of ambulation, laboured breathing or weight loss > 20% mean body weight per cage^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14(1):309-17. [Content Brief]

[2]. Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25(5):1108-17. [Content Brief]

[3]. Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167(4):881-91. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7913 mL	13.9563 mL	27.9127 mL	69.7817 mL
	5 mM	0.5583 mL	2.7913 mL	5.5825 mL	13.9563 mL
	10 mM	0.2791 mL	1.3956 mL	2.7913 mL	6.9782 mL
	15 mM	0.1861 mL	0.9304 mL	1.8608 mL	4.6521 mL
	20 mM	0.1396 mL	0.6978 mL	1.3956 mL	3.4891 mL
	25 mM	0.1117 mL	0.5583 mL	1.1165 mL	2.7913 mL
	30 mM	0.0930 mL	0.4652 mL	0.9304 mL	2.3261 mL
	40 mM	0.0698 mL	0.3489 mL	0.6978 mL	1.7445 mL
	50 mM	0.0558 mL	0.2791 mL	0.5583 mL	1.3956 mL
	60 mM	0.0465 mL	0.2326 mL	0.4652 mL	1.1630 mL
	80 mM	0.0349 mL	0.1745 mL	0.3489 mL	0.8723 mL
	100 mM	0.0279 mL	0.1396 mL	0.2791 mL	0.6978 mL

Keywords

Bendamustine

6 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Bendamustine

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Bendamustine

Biological Activity

Chemical Information

Publications (6)

용액&용해도

Protocol

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Bendamustine

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Bendamustine

Biological Activity

Chemical Information

Publications (6)

용액&용해도

Protocol

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Bendamustine Related Classifications

HY-13567 Related Classifications